

Applicants: Novak et al.

Serial No.: 10/659,684

Filed: September 10, 2003

For: CYTOKINE ZALPHA11 LIGAND

Amendments to the Claims:

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are noted to indicated changes made and the text of pending claims not being amended are presented clean. Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

2. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

3. (original) An isolated polypeptide comprising a sequence of amino acid residues that is identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

4. (original) The isolated polypeptides of claims (1), (2), or (3), wherein the polypeptide binds the zalpha11 Ligand receptor as shown in SEQ ID NO:115.

5. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 32 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

6. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2.

Applicants: Novak et al.

Serial No.: 10/659,684

Filed: September 10, 2003

For: CYTOKINE ZALPHA11 LIGAND

7. (original) An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from residues 32 (Gln) to 162 (Ser), wherein the polypeptide has an N-terminal Met.

8. (canceled)

9. (original) A pharmaceutical composition comprising a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2, a pharmaceutically acceptable vehicle.

10. (original) A pharmaceutical composition comprising a polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2, a pharmaceutically acceptable vehicle.

11. (original) A pharmaceutical composition comprising a polypeptide comprising a sequence of amino acid residues from residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2, a pharmaceutically acceptable vehicle.

Claims 12-47 (canceled)